Cancers 2011, 3(2), 2014-2031; doi:10.3390/cancers3022014
Review

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects

* email, email, email and email
Received: 4 February 2011; in revised form: 19 March 2011 / Accepted: 24 March 2011 / Published: 18 April 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Current clinical trials of epidermal growth factor receptor (EGFR)-targeted therapies are mostly guided by a classical approach coming from the cytotoxic paradigm. The predominant view is that the efficacy of EGFR antagonists correlates with skin rash toxicity and induction of objective clinical response. Clinical benefit from EGFR-targeted therapies is well documented; however, chronic use in advanced cancer patients has been limited due to cumulative and chemotherapy-enhanced toxicity. Here we analyze different pieces of data from mechanistic and clinical studies with the anti-EGFR monoclonal antibody Nimotuzumab, which provides several clues to understand how this antibody may induce a biological control of tumor growth while keeping a low toxicity profile. Based on these results and the current state of the art on EGFR-targeted therapies, we discuss the need to evaluate new therapeutic approaches using anti-EGFR agents, which would have the potential of transforming advanced cancer into a long-term controlled chronic disease.
Keywords: EGFR; Nimotuzumab; cancer treatment; targeted therapy; biological therapy
PDF Full-text Download PDF Full-Text [615 KB, uploaded 18 April 2011 16:00 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Perez, R.; Moreno, E.; Garrido, G.; Crombet, T. EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects. Cancers 2011, 3, 2014-2031.

AMA Style

Perez R, Moreno E, Garrido G, Crombet T. EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects. Cancers. 2011; 3(2):2014-2031.

Chicago/Turabian Style

Perez, Rolando; Moreno, Ernesto; Garrido, Greta; Crombet, Tania. 2011. "EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects." Cancers 3, no. 2: 2014-2031.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert